Table 1.

Characteristics of participants with available HCV Core-Envelope 2 segment sequence in the VIDUS cohort, 1996-2012, Vancouver, Canada (n=655).

Characteristics	Overall (n=655)
Female sex (vs. male sex)	162 (25%)
Age (median (Q1-Q3))	36 (31-42)
Age <40 years (vs. ≥40 years)	437 (67%)
High school education or higher (vs. less than high school)*	126 (19%)^
Unstable housing (vs. stable)†	452 (69%)
Years injecting (median (Q1-Q3))	15 (6-23)
HCV acute/recent (vs. not)	40 (6%)
HIV infection (vs. none)†	164 (25%)
Currently enrolled in methadone treatment (vs. yes)	82 (13%)#
Syringe borrowing (vs. none)†	268 (41%)
Crack use (vs. none)†	159 (24%)
Cocaine injecting (vs. none)†	546 (83%)
Heroin injecting (vs. none)†	473 (72%)
Speedball injecting (vs. none)†	266 (41%)
Genotype
1a	313 (48%)
1b	41 (6%)
2a	20 (3%)
2b	46 (7%)
3a	213 (33%)
4a	4 (<1%)
6a	8 (1%)
6e	1 (<1%)
Unclassifiable	9 (1%)

Percentages indicate column percentages

^*At the time of enrolment

^†In the last 6 months prior to enrolment

^{^}Data unavailable for 2 participants

^#Data unavailable for 3 participants.

Abbreviations: HIV = human immunodeficiency virus; HCV hepatitis C virus